-

BostonGene Highlights Its AI-Powered Multiomics Platform at hubXchange’s Immuno-Oncology Xchange Boston 2024

Roundtable Session to Focus on Multiomic Immune Biomarker Strategies for Optimizing Drug Development and Patient Outcomes

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced that it will participate in the hubXchange’s Immuno-Oncology Xchange - Boston 2024, taking place June 18 in Boston, Massachusetts. The event brings together executives from pharma and biotech to address and find solutions to the key issues that are currently faced in Immuno-Oncology.

During the event, BostonGene will lead a roundtable discussion:
Multiomic immune biomarker selection for novel IO response and toxicity assessment: tissue, blood, plasma, or all of the above?

  • Tuesday, June 18 | 11:20 AM ET
  • Speaker: Michael Goldberg, PhD, VP, Research & Development, BostonGene

This session will explore the utilization of immune biomarker strategies to enhance drug development and improve patient outcomes. The focus will be on current applications, technological advancements, novel approaches and the necessary validation and regulatory processes. By addressing these aspects, the session aims to highlight how these strategies can significantly improve therapeutic results and personalize treatment plans.

"I'm excited to participate in the hubXchange’s Immuno-Oncology Xchange and discuss how immune biomarker strategies can revolutionize drug development and patient care. By leveraging advanced technologies and comprehensive biomarker profiles, we have the potential to drastically enhance therapeutic outcomes and tailor treatments to individual patients' needs," said Michael Goldberg, PhD, VP, Research & Development at BostonGene.

About BostonGene Corporation

BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.

Contacts

BostonGene
Erin Keleher O’Reilly
+1-617-283-2285
Erin.Oreilly@BostonGene.com

Industry:

BostonGene

Release Versions
English

Contacts

BostonGene
Erin Keleher O’Reilly
+1-617-283-2285
Erin.Oreilly@BostonGene.com

Social Media Profiles
BostonGene
BostonGene - Twitter
More News From BostonGene

BostonGene Announces Strategic Collaboration with Daiichi Sankyo to Accelerate Drug Development Through AI-Driven Multimodal Analytics

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Daiichi Sankyo (TSE: 4568). The collaboration will integrate AI-driven translational intelligence into the core of an antibody drug conjugate (ADC) development program of Daiichi Sankyo to move beyond standard exploratory biomarker analysis and deliver decision-ready insights that directly inform patient selection strategies,...

Independent Multi-Vendor Study Validates BostonGene’s AI for Precision HER2 Scoring

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced another major independent validation of its AI and machine learning (ML) capabilities in a landmark blinded, multi-vendor HER2 benchmarking study. The results, published in the Modern Pathology article, “Agreement Across 10 Artificial Intelligence Models in Assessing Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Whole-Slide Ima...

BostonGene Announces Collaboration with Ottimo Pharma to Optimize and Accelerate Development of First-in-Class PD-1/VEGFR2 Immuno-Oncology Therapy Using AI

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Ottimo Pharma Limited (“Ottimo”), an innovative, clinical-stage biotech company developing one-of-a-kind PD-1/VEGFR2 dual paratopic antibodies to extend the lives of patients living with cancer. The partnership will utilize BostonGene’s advanced artificial intelligence (AI) platform to apply multiomic analytics and expedite th...
Back to Newsroom